Home|New Products||||Technical support

CD19 antibody - HS-439 003

CD19 is a B-lymphocyte antigen
Rabbit polyclonal purified antibody
Cat. No.: HS-439 003
Amount: 200 µl
Price: $370.00
Cat. No. HS-439 003 200 µl specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 200 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Applications
 
WB: 1 : 250 (AP-staining) gallery  
ICC: 1 : 1000 gallery  
IHC: 1 : 500 gallery  
IHC-P: 1 : 100 gallery  
Immunogen Synthetic peptide corresponding to AA 527 to 547 from mouse CD19 (UniProt Id: P25918)
Reactivity Reacts with: mouse (P25918).
No signal: human (P15391), rat.
Other species not tested yet.
Specificity Specific for mouse CD19 without cross-reactivity to human and rat CD19.
Data sheet hs-439_003.pdf
Cat. No.: HS-439 003
Amount: 200 µl
Price: $370.00

Indirect immunostaining of a formalin fixed paraffin-embedded mouse breast cancer model with rabbit anti-mouse CD19 (cat. no.: HS-439 003; DAB). Nuclei have been visualized by haematoxylin staining (blue).

Background

CD19 (Cluster of Differentiation 19) is a B cell-restricted signal-transduction molecule that plays an important role in the regulation of development, activation, and differentiation of B-lymphocytes. CD19 is considered as a biomarker for B-cells because of its continued expression from very early B cell development stages, being evident already on pro-B cells and on all later B cell stages, until plasma cell terminal differentiation, when its expression is lost. In complex with CD21 (complement receptor-2), CD81 and CD225 (Leu-13), CD19 functions as a dominant signaling receptor on the surface of mature B cells (1). CD19 is instrumental in B cell homeostasis and lowers the threshold of B cell receptor crosslinking necessary to effect B-cell activation and sustain proliferation upon antigen encounter (2). Dysregulated CD19 expression has been implicated in several autoimmune diseases and CD19 is expressed in most acute lymphoblastic leukemias (ALL), chronic lymphocytic leukemias (CLL) and other B cell lymphomas (3). Therefore, CD19 has gained attention as a potential target in the therapy of B-cell malignancies (4).

Protocols